Eupraxia Shares Climb After FDA Fast-Track Designation for Study
2023年6月14日 - 12:04AM
Dow Jones News
By Robb M. Stewart
Eupraxia Pharmaceuticals' shares advanced Tuesday after the U.S.
Food and Drug Administration granted fast-track designation for the
investigation of the biotechnology company's lead product
candidate, EP-104IAR, in the treatment of adults with
osteoarthritis of the knee.
In morning trading, the shares were 9.9% higher at C$7.88. The
stock has more than doubled so far this year.
Eupraxia said it continues to advance an ongoing Phase 2 trial
evaluating EP-104IAR's safety and efficacy as a treatment candidate
for knee osteoarthritis and expects to report top-line data results
in the second quarter of this year.
The FDA's fast-track process is designed to help the development
and speed the review of drugs that treat serious conditions and
fill an unmet medical need.
In late May, Eupraxia said it reached the last patient to visit
in its Phase 2 clinical trial of EP-104IAR for osteoarthritis, a
milestone toward the completion of the study.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 13, 2023 10:49 ET (14:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Eupraxia Pharmaceuticals (TSX:EPRX)
過去 株価チャート
から 4 2024 まで 5 2024
Eupraxia Pharmaceuticals (TSX:EPRX)
過去 株価チャート
から 5 2023 まで 5 2024
